{
  "id": 14969986,
  "title": "Raymond James reiterates Palvella stock Strong Buy on conference data",
  "url": "https://urgent.news/2026/10/16/raymond-james-reiterates-palvella-stock-strong-buy-on-conference-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-16T14:10:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/raymond-james-reiterates-palvella-stock-strong-buy-on-conference-data-93CH-4954396"
  },
  "original_language": "en",
  "account": "Raymond James maintained its Strong Buy rating and raised the price target to $226.00 for Palvella Therapeutics (NASDAQ: PVLA) shares, following a presentation at a dermatology conference. This positive assessment aligns with the consensus among analysts, who continue to recommend Strong Buy with price targets spanning from $205 to $267. The update stems from Palvella's presentation of two posters at the 2026 Pediatric Dermatology Research Alliance Annual Conference, held from October 15-17, 2026. The posters showcased pediatric subgroup analyses from Phase 3 SELVA and Phase 2 TOIVA clinical studies. The SELVA analysis, involving patients aged 6-11 and 12-17, demonstrated reductions in lesion height, leaking/bleeding, and vesicle appearance following 168 days of QTORIN rapamycin treatment. The TOIVA pediatric analysis reported enhancements in lesion severity and bleeding by Week 24, along with high treatment satisfaction. Raymond James highlighted that treatment response appears more favorable in younger age groups. Despite the positive clinical data, Palvella Therapeutics' stock has slipped 8.2% in the past week, though it has still gained a substantial 74% over the past year. The stock is currently priced at $127.34, according to InvestingPro's analysis, it appears overvalued. Palvella Therapeutics recently reported a second-quarter loss of $1.52 per share, which exceeded the $1.16 loss predicted by analysts. However, the company ended the quarter with around $251 million in cash, providing a financial cushion for its development and launch preparations. The lead drug, QTORIN rapamycin, showed impressive Phase III results, with a 95% improvement rate in microcystic lymphatic malformations, and is slated for an NDA submission in the second half of 2026. Palvella aims for FDA approval by the first half of 2027 as it bolsters commercial hiring and sales coverage. William Blair initiated coverage of Palvella with an Outperform rating, valuing the company at $266 per share, based on the promising potential of its QTORIN platform.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "DA Davidson reiterates U.S. Bancorp stock Buy on strong revenue",
        "url": "https://urgent.news/2026/10/16/da-davidson-reiterates-u-s-bancorp-stock-buy-on-strong-revenue",
        "published": "2026-10-16T15:10:41.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}